Drug Approval | July 02, 2022
Ascentage Pharma gets IND clearance by the US FDA for novel EED Inhibitor APG-5918
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
We must try to make the health care system more accessible for people with disabilities
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Doctors will study for a Master of Surgery or Master of Medicine degree at Edge Hill University.
The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Subscribe To Our Newsletter & Stay Updated
